Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Negative 93.6%

Neg 93.6% Neu 0% Pos 0%

Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $6 to $4.